Crizotinib: from discovery to accelerated development to front-line treatment.

Fiona Blackhall, F Capuzzo

Research output: Other contributionpeer-review

Abstract

Ann Oncol 2016; 27: iii35–iii41 (doi: 10.1093/annonc/mdw304)

An error has been corrected on p. iii40, where trials were numbered incorrectly. The corrected sentence reads:

In a joint analysis of 194 patients with RECIST-defined disease progression in the PROFILE 1001 and PROFILE 1005 studies, 120 continued to receive crizotinib [36].
Original languageEnglish
TypeCorrigendum
DOIs
Publication statusPublished - 2017

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Crizotinib: from discovery to accelerated development to front-line treatment.'. Together they form a unique fingerprint.

Cite this